Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fenticonazole→

Fenticonazole Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
72479-26-6
Molecular formula
C24H20Cl2N2OS
Molecular weight
455.4 g/mol
Drug class
Imidazole azole antifungalergosterol-biosynthesis inhibitor
Mechanism of action
Inhibits fungal lanosterol 14-alpha-demethylase and disrupts ergosterol synthesis, impairing fungal membrane structure and function. It also has local antibacterial activity against selected organisms.
Indications / reported uses
  • Topical treatment of vulvovaginal candidiasis and selected superficial fungal skin infections with authorised vaginal or dermatological formulations; route and product-specific indications are not interchangeable

Sources: NLM MeSH — Fenticonazole · PubMed — Fenticonazole clinical antifungal use · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fenticonazole Environmental Risk Assessment (ERA) (the Fenticonazole ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.